The FDA usually follows the recommendations of its advisory panels. Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. The FDA decision is expected by the end of 2015, an Eli Lilly spokesperson said.
Government and Regulations
FDA panel says benefits of necitumumab for squamous NSCLC outweigh risks
